BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Linas BP, Barter DM, Leff JA, Assoumou SA, Salomon JA, Weinstein MC, Kim AY, Schackman BR. The hepatitis C cascade of care: identifying priorities to improve clinical outcomes. PLoS One 2014;9:e97317. [PMID: 24842841 DOI: 10.1371/journal.pone.0097317] [Cited by in Crossref: 77] [Cited by in F6Publishing: 80] [Article Influence: 9.6] [Reference Citation Analysis]
Number Citing Articles
1 Jordan AE, Cleland CM, Schackman BR, Wyka K, Perlman DC, Nash D. Hepatitis C Virus (HCV) Care Continuum Outcomes and HCV Community Viral Loads Among Patients in an Opioid Treatment Program. J Infect Dis 2020;222:S335-45. [PMID: 32877560 DOI: 10.1093/infdis/jiz686] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Carmichael JM, Meier J, Robinson A, Taylor J, Higgins DT, Patel S. Leveraging electronic medical record data for population health management in the Veterans Health Administration: Successes and lessons learned. Am J Health Syst Pharm 2017;74:1447-59. [PMID: 28887346 DOI: 10.2146/ajhp161048] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
3 Fagundes RN, Ferreira LE, Pace FH. [Health-Related Quality of Life in patients with hepatitis C treated with dual and triple therapy]. Rev Esc Enferm USP 2015;49:939-45. [PMID: 27419677 DOI: 10.1590/S0080-623420150000600009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
4 Starbird LE, Budhathoki C, Han HR, Sulkowski MS, Reynolds NR, Farley JE. Nurse case management to improve the hepatitis C care continuum in HIV co-infection: Results of a randomized controlled trial. J Viral Hepat 2020;27:376-86. [PMID: 31750598 DOI: 10.1111/jvh.13241] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
5 Barocas JA, Tasillo A, Eftekhari Yazdi G, Wang J, Vellozzi C, Hariri S, Isenhour C, Randall L, Ward JW, Mermin J, Salomon JA, Linas BP. Population-level Outcomes and Cost-Effectiveness of Expanding the Recommendation for Age-based Hepatitis C Testing in the United States. Clin Infect Dis 2018;67:549-56. [PMID: 29420742 DOI: 10.1093/cid/ciy098] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 12.0] [Reference Citation Analysis]
6 Madden A, Hopwood M, Neale J, Treloar C. Beyond cure: patient reported outcomes of hepatitis C treatment among people who inject drugs in Australia. Harm Reduct J 2018;15:42. [PMID: 30111327 DOI: 10.1186/s12954-018-0248-4] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 5.5] [Reference Citation Analysis]
7 Kinnard EN, Bluthenthal RN, Kral AH, Wenger LD, Lambdin BH. The naloxone delivery cascade: Identifying disparities in access to naloxone among people who inject drugs in Los Angeles and San Francisco, CA. Drug Alcohol Depend 2021;225:108759. [PMID: 34058540 DOI: 10.1016/j.drugalcdep.2021.108759] [Reference Citation Analysis]
8 Isho NY, Kachlic MD, Marcelo JC, Martin MT. Pharmacist-initiated hepatitis C virus screening in a community pharmacy to increase awareness and link to care at the medical center. J Am Pharm Assoc (2003) 2017;57:S259-64. [PMID: 28506379 DOI: 10.1016/j.japh.2017.03.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
9 Milne R, Price M, Wallace B, Drost A, Haigh-gidora I, Nezil FA, Fraser C. From principles to practice: Description of a novel equity-based HCV primary care treatment model for PWID. International Journal of Drug Policy 2015;26:1020-7. [DOI: 10.1016/j.drugpo.2015.07.009] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.1] [Reference Citation Analysis]
10 Yeboah-Korang A, Beig MI, Khan MQ, Goldstein JL, Macapinlac DM, Maurer D, Sonnenberg A, Fimmel CJ. Hepatitis C Screening in Commercially Insured U.S. Birth-cohort Patients: Factors Associated with Testing and Effect of an EMR-based Screening Alert. J Transl Int Med 2018;6:82-9. [PMID: 29984203 DOI: 10.2478/jtim-2018-0012] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
11 Morgan MC, Spindler H, Nambuya H, Nalwa GM, Namazzi G, Waiswa P, Otieno P, Cranmer J, Walker DM. Clinical cascades as a novel way to assess physical readiness of facilities for the care of small and sick neonates in Kenya and Uganda. PLoS One 2018;13:e0207156. [PMID: 30462671 DOI: 10.1371/journal.pone.0207156] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
12 Mazzucco W, Vitale F, Mazzola S, Amodio R, Zarcone M, Alba D, Marotta C, Cusimano R, Allemani C. Does access to care play a role in liver cancer survival? The ten-year (2006-2015) experience from a population-based cancer registry in Southern Italy. BMC Cancer 2021;21:307. [PMID: 33761907 DOI: 10.1186/s12885-021-07935-0] [Reference Citation Analysis]
13 Harvey L, Taylor JL, Assoumou SA, Kehoe J, Schechter-Perkins EM, Bernstein E, Walley AY. Sexually Transmitted and Blood-borne Infections Among Patients Presenting to a Low-barrier Substance Use Disorder Medication Clinic. J Addict Med 2021;15:461-7. [PMID: 34734572 DOI: 10.1097/ADM.0000000000000801] [Reference Citation Analysis]
14 Sherbuk JE, McManus KA, Kemp Knick T, Canan CE, Flickinger T, Dillingham R. Disparities in Hepatitis C Linkage to Care in the Direct Acting Antiviral Era: Findings From a Referral Clinic With an Embedded Nurse Navigator Model. Front Public Health 2019;7:362. [PMID: 31828056 DOI: 10.3389/fpubh.2019.00362] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
15 Boodram B, Kaufmann M, Aronsohn A, Hamlish T, Peregrine Antalis E, Kim K, Wolf J, Rodriguez I, Millman AJ, Johnson D. Case Management and Capacity Building to Enhance Hepatitis C Treatment Uptake at Community Health Centers in a Large Urban Setting. Fam Community Health. 2020;43:150-160. [PMID: 32079971 DOI: 10.1097/fch.0000000000000253] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
16 Epstein RL, Sabharwal V, Wachman EM, Saia KA, Vellozzi C, Hariri S, Linas BP. Perinatal Transmission of Hepatitis C Virus: Defining the Cascade of Care. J Pediatr 2018; 203: 34-40. e1. [PMID: 30170857 DOI: 10.1016/j.jpeds.2018.07.006] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 6.5] [Reference Citation Analysis]
17 Metsch LR, Feaster DJ, Gooden LK, Masson C, Perlman DC, Jain MK, Matheson T, Nelson CM, Jacobs P, Tross S, Haynes L, Lucas GM, Colasanti JA, Rodriguez A, Drainoni ML, Osorio G, Nijhawan AE, Jacobson JM, Sullivan M, Metzger D, Vergara-Rodriguez P, Lubelchek R, Duan R, Batycki JN, Matthews AG, Munoz F, Jelstrom E, Mandler R, Del Rio C. Care Facilitation Advances Movement Along the Hepatitis C Care Continuum for Persons With Human Immunodeficiency Virus, Hepatitis C, and Substance Use: A Randomized Clinical Trial (CTN-0064). Open Forum Infect Dis 2021;8:ofab334. [PMID: 34377726 DOI: 10.1093/ofid/ofab334] [Reference Citation Analysis]
18 Bouare N, Keita M, Delwaide J. Comment on review article: Chronic hepatitis C virus infection cascade of care in pediatric patients. World J Gastroenterol 2022; 28(14): 1494-1498 [DOI: 10.3748/wjg.v28.i14.1494] [Reference Citation Analysis]
19 Nitsche B, Miller SC, Giorgio M, Berry CA, Muir A. Improving Hepatitis C Identification: Technology Alone Is Not the Answer. Health Promot Pract 2018;19:506-12. [PMID: 28893101 DOI: 10.1177/1524839917725501] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
20 Jonas MC, Rubenstein K, Watson E, Basra S, Horberg M. A Comprehensive Coordinator Supported Hepatitis C Virus Testing and Linkage to Treatment Program at Kaiser Permanente Mid-Atlantic States. Viruses 2021;13:2140. [PMID: 34834947 DOI: 10.3390/v13112140] [Reference Citation Analysis]
21 Isenhour CJ, Hariri SH, Hales CM, Vellozzi CJ. Hepatitis C Antibody Testing in a Commercially Insured Population, 2005-2014. Am J Prev Med 2017;52:625-31. [PMID: 28161033 DOI: 10.1016/j.amepre.2016.12.016] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
22 Jordan AE, Perlman DC, Reed J, Smith DJ, Hagan H. Patterns and Gaps Identified in a Systematic Review of the Hepatitis C Virus Care Continuum in Studies among People Who Use Drugs. Front Public Health 2017;5:348. [PMID: 29326922 DOI: 10.3389/fpubh.2017.00348] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
23 Iversen J, Dore GJ, Starr M, Catlett B, Cunningham P, Geddes L, Maher L. Estimating the Consensus hepatitis C Cascade of Care among people who inject drugs in Australia: Pre and post availability of direct acting antiviral therapy. Int J Drug Policy 2020;83:102837. [PMID: 32645585 DOI: 10.1016/j.drugpo.2020.102837] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
24 Kamali I, Shumbusho F, Barnhart DA, Nyirahabihirwe F, Gakuru JP, Dusingizimana W, Nizeyumuremyi E, Habinshuti P, Walker S, Makuza JD, Serumondo J, Nshogoza Rwibasira G, Ndahimana JD. Time to complete hepatitis C cascade of care among patients identified during mass screening campaigns in rural Rwanda: a retrospective cohort study. BMC Infect Dis 2022;22:272. [PMID: 35313817 DOI: 10.1186/s12879-022-07271-z] [Reference Citation Analysis]
25 Geiger R, Steinert J, McElwee G, Carver J, Montanez R, Niewoehner J, Clark C, Reilley B. A Regional Analysis of Hepatitis C Virus Collaborative Care With Pharmacists in Indian Health Service Facilities. J Prim Care Community Health 2018;9:2150132718807520. [PMID: 30348039 DOI: 10.1177/2150132718807520] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
26 Elbahrawy A, Ibrahim MK, Eliwa A, Alboraie M, Madian A, Aly HH. Current situation of viral hepatitis in Egypt. Microbiol Immunol 2021;65:352-72. [PMID: 33990999 DOI: 10.1111/1348-0421.12916] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
27 Machado SM, Almeida C Neto, Pinho JRR, Malta FM, Capuani L, Campos AF, Abreu FRM, Nastri ACSS, Santana RAF, Sabino EC, Mendes-Correa MC. Hepatitis C among blood donors: cascade of care and predictors of loss to follow-up. Rev Saude Publica 2017;51:40. [PMID: 28489184 DOI: 10.1590/S1518-8787.2017051006468] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
28 Young KL, Huang W, Horsburgh CR, Linas BP, Assoumou SA. Eighteen- to 30-year-olds more likely to link to hepatitis C virus care: an opportunity to decrease transmission. J Viral Hepat. 2016;23:274-281. [PMID: 26572798 DOI: 10.1111/jvh.12489] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
29 Tsui JI, Miller CM, Scott JD, Corcorran MA, Dombrowski JC, Glick SN. Hepatitis C continuum of care and utilization of healthcare and harm reduction services among persons who inject drugs in Seattle. Drug Alcohol Depend 2019;195:114-20. [PMID: 30611979 DOI: 10.1016/j.drugalcdep.2018.11.026] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
30 Seña AC, Willis SJ, Hilton A, Anderson A, Wohl DA, Hurt CB, Muir AJ. Efforts at the Frontlines: Implementing a Hepatitis C Testing and Linkage-to-Care Program at the Local Public Health Level. Public Health Rep 2016;131 Suppl 2:57-64. [PMID: 27168663 DOI: 10.1177/00333549161310S210] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
31 Starbird LE, Han HR, Sulkowski MS, Budhathoki C, Reynolds NR, Farley JE. Care2Cure: A randomized controlled trial protocol for evaluating nurse case management to improve the hepatitis C care continuum within HIV primary care. Res Nurs Health 2018;41:417-27. [PMID: 30152537 DOI: 10.1002/nur.21903] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
32 Calner P, Sperring H, Ruiz-Mercado G, Miller NS, Andry C, Battisti L, Scrudder K, Shea F, Chan A, Schechter-Perkins EM. HCV screening, linkage to care, and treatment patterns at different sites across one academic medical center. PLoS One 2019;14:e0218388. [PMID: 31291275 DOI: 10.1371/journal.pone.0218388] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
33 Ismail F, Haq S, El-Garawani I, Abdelsameea E. Hepatitis C Virus Infection in Eastern Libya: Efforts Needed to Improve HCV Testing and Linkage to Care in the Resource-Limited Setting. Trop Med Infect Dis 2022;7:14. [PMID: 35202210 DOI: 10.3390/tropicalmed7020014] [Reference Citation Analysis]
34 Cranmer JN, Dettinger J, Calkins K, Kibore M, Gachuno O, Walker D. Beyond signal functions in global obstetric care: Using a clinical cascade to measure emergency obstetric readiness. PLoS One 2018;13:e0184252. [PMID: 29474397 DOI: 10.1371/journal.pone.0184252] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
35 Rupasinghe D, Choi JY, Kumarasamy N, Pujari S, Sun LP, Merati TP, Lee MP, Kinh NV, Kiertiburanakul S, Do CD, Avihingsanon A, Ross J, Jiamsakul A; o n behalf of IeDEA Asia-Pacific. Viral hepatitis and the cascade of care among people living with HIV in the Asia-Pacific. HIV Med 2022. [PMID: 35218151 DOI: 10.1111/hiv.13280] [Reference Citation Analysis]
36 Hawks L, Norton BL, Cunningham CO, Fox AD. The Hepatitis C virus treatment cascade at an urban postincarceration transitions clinic. J Viral Hepat 2016;23:473-8. [PMID: 26856967 DOI: 10.1111/jvh.12512] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
37 Morgan JR, Kim AY, Naggie S, Linas BP. The Effect of Shorter Treatment Regimens for Hepatitis C on Population Health and Under Fixed Budgets. Open Forum Infect Dis 2018;5:ofx267. [PMID: 29354660 DOI: 10.1093/ofid/ofx267] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
38 Assoumou SA, Tasillo A, Vellozzi C, Eftekhari Yazdi G, Wang J, Nolen S, Hagan L, Thompson W, Randall LM, Strick L, Salomon JA, Linas BP. Cost-effectiveness and Budgetary Impact of Hepatitis C Virus Testing, Treatment, and Linkage to Care in US Prisons. Clin Infect Dis 2020;70:1388-96. [PMID: 31095676 DOI: 10.1093/cid/ciz383] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
39 Lee JS, Choi HJ, Lee HW, Kim BK, Park JY, Kim DY, Ahn SH, Kim SU. Screening, confirmation, and treatment rates of hepatitis C virus infection in a tertiary academic medical center in South Korea. J Gastroenterol Hepatol 2021. [PMID: 33788314 DOI: 10.1111/jgh.15514] [Reference Citation Analysis]
40 Barocas JA, Morgan JR, Fiellin DA, Schackman BR, Eftekhari Yazdi G, Stein MD, Freedberg KA, Linas BP. Cost-effectiveness of integrating buprenorphine-naloxone treatment for opioid use disorder into clinical care for persons with HIV/hepatitis C co-infection who inject opioids. Int J Drug Policy 2019;72:160-8. [PMID: 31085063 DOI: 10.1016/j.drugpo.2019.05.010] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
41 Safreed-Harmon K, Blach S, Aleman S, Bollerup S, Cooke G, Dalgard O, Dillon JF, Dore GJ, Duberg AS, Grebely J, Boe Kielland K, Midgard H, Porter K, Razavi H, Tyndall M, Weis N, Lazarus JV. The Consensus Hepatitis C Cascade of Care: Standardized Reporting to Monitor Progress Toward Elimination. Clin Infect Dis. 2019;69:2218-2227. [PMID: 31352481 DOI: 10.1093/cid/ciz714] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 11.5] [Reference Citation Analysis]
42 Crowley D, Cullen W, Laird E, Lambert JS, Mc Hugh T, Murphy C, Van Hout MC. Exploring Patient Characteristics and Barriers to Hepatitis C Treatment in Patients on Opioid Substitution Treatment Attending a Community Based Fibro-scanning Clinic. J Transl Int Med 2017;5:112-9. [PMID: 28721344 DOI: 10.1515/jtim-2017-0017] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
43 Castrejón M, Chew KW, Javanbakht M, Humphries R, Saab S, Klausner JD. Implementation of a Large System-Wide Hepatitis C Virus Screening and Linkage to Care Program for Baby Boomers. Open Forum Infect Dis 2017;4:ofx109. [PMID: 28752101 DOI: 10.1093/ofid/ofx109] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 6.2] [Reference Citation Analysis]
44 Iversen J, Grebely J, Catlett B, Cunningham P, Dore GJ, Maher L. Estimating the cascade of hepatitis C testing, care and treatment among people who inject drugs in Australia. International Journal of Drug Policy 2017;47:77-85. [DOI: 10.1016/j.drugpo.2017.05.022] [Cited by in Crossref: 63] [Cited by in F6Publishing: 61] [Article Influence: 12.6] [Reference Citation Analysis]
45 Do A, Reau NS. Chronic Viral Hepatitis: Current Management and Future Directions. Hepatol Commun 2020;4:329-41. [PMID: 32140652 DOI: 10.1002/hep4.1480] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
46 Hsieh YH, Rothman RE, Laeyendecker OB, Kelen GD, Avornu A, Patel EU, Kim J, Irvin R, Thomas DL, Quinn TC. Evaluation of the Centers for Disease Control and Prevention Recommendations for Hepatitis C Virus Testing in an Urban Emergency Department. Clin Infect Dis. 2016;62:1059-1065. [PMID: 26908800 DOI: 10.1093/cid/ciw074] [Cited by in Crossref: 50] [Cited by in F6Publishing: 43] [Article Influence: 8.3] [Reference Citation Analysis]
47 Do A, Mittal Y, Liapakis A, Cohen E, Chau H, Bertuccio C, Sapir D, Wright J, Eggers C, Drozd K, Ciarleglio M, Deng Y, Lim JK. Drug Authorization for Sofosbuvir/Ledipasvir (Harvoni) for Chronic HCV Infection in a Real-World Cohort: A New Barrier in the HCV Care Cascade. PLoS One. 2015;10:e0135645. [PMID: 26312999 DOI: 10.1371/journal.pone.0135645] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 6.1] [Reference Citation Analysis]
48 Linas BP, Barter DM, Morgan JR, Pho MT, Leff JA, Schackman BR, Horsburgh CR, Assoumou SA, Salomon JA, Weinstein MC, Freedberg KA, Kim AY. The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection. Ann Intern Med 2015;162:619-29. [PMID: 25820703 DOI: 10.7326/M14-1313] [Cited by in Crossref: 76] [Cited by in F6Publishing: 41] [Article Influence: 10.9] [Reference Citation Analysis]
49 Bouare N, Keita M, Delwaide J. Comment on review article: Chronic hepatitis C virus infection cascade of care in pediatric patients. WJG 2022;28:1494-8. [DOI: 10.3748/wjg.v28.i14.1494] [Reference Citation Analysis]
50 Kileng H, Gutteberg T, Goll R, Paulssen EJ. Screening for hepatitis C in a general adult population in a low-prevalence area: the Tromsø study. BMC Infect Dis 2019;19:189. [PMID: 30808290 DOI: 10.1186/s12879-019-3832-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
51 Jordan AE, Des Jarlais DC, Arasteh K, McKnight C, Nash D, Perlman DC. Incidence and prevalence of hepatitis c virus infection among persons who inject drugs in New York City: 2006-2013. Drug Alcohol Depend 2015;152:194-200. [PMID: 25891230 DOI: 10.1016/j.drugalcdep.2015.03.039] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 5.1] [Reference Citation Analysis]
52 Perlman DC, Jordan AE, Nash D. Conceptualizing Care Continua: Lessons from HIV, Hepatitis C Virus, Tuberculosis and Implications for the Development of Improved Care and Prevention Continua. Front Public Health 2016;4:296. [PMID: 28119910 DOI: 10.3389/fpubh.2016.00296] [Cited by in Crossref: 19] [Cited by in F6Publishing: 29] [Article Influence: 3.8] [Reference Citation Analysis]
53 Høj SB, Minoyan N, Artenie AA, Grebely J, Bruneau J. The role of prevention strategies in achieving HCV elimination in Canada: what are the remaining challenges? CanLivJ 2018;1:4-13. [DOI: 10.3138/canlivj.1.2.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
54 Scott J, Fagalde M, Baer A, Glick S, Barash E, Armstrong H, Kowdley KV, Golden MR, Millman AJ, Nelson NP, Canary L, Messerschmidt M, Patel P, Ninburg M, Duchin J. A Population-Based Intervention to Improve Care Cascades of Patients With Hepatitis C Virus Infection. Hepatol Commun 2021;5:387-99. [PMID: 33681674 DOI: 10.1002/hep4.1627] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
55 Groessl EJ, Sklar M, Laurent DD, Lorig K, Ganiats TG, Ho SB. Cost-Effectiveness of the Hepatitis C Self-Management Program. Health Educ Behav 2017;44:113-22. [PMID: 27206463 DOI: 10.1177/1090198116639239] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
56 Reed JR, Jordan AE, Perlman DC, Smith DJ, Hagan H. The HCV care continuum among people who use drugs: protocol for a systematic review and meta-analysis. Syst Rev 2016;5:110. [PMID: 27401499 DOI: 10.1186/s13643-016-0293-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
57 Ward T, Gordon J, Bennett H, Webster S, Sugrue D, Jones B, Brenner M, McEwan P. Tackling the burden of the hepatitis C virus in the UK: characterizing and assessing the clinical and economic consequences. Public Health 2016;141:42-51. [PMID: 27932014 DOI: 10.1016/j.puhe.2016.08.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
58 Saine ME, Szymczak JE, Moore TM, Bamford LP, Barg FK, Forde KA, Schnittker J, Holmes JH, Mitra N, Lo Re V 3rd. The impact of disease-related knowledge on perceptions of stigma among patients with Hepatitis C Virus (HCV) infection. PLoS One 2021;16:e0258143. [PMID: 34610030 DOI: 10.1371/journal.pone.0258143] [Reference Citation Analysis]
59 Bourgi K, Brar I, Baker-Genaw K. Health Disparities in Hepatitis C Screening and Linkage to Care at an Integrated Health System in Southeast Michigan. PLoS One 2016;11:e0161241. [PMID: 27525983 DOI: 10.1371/journal.pone.0161241] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 5.8] [Reference Citation Analysis]
60 Jordan AE, Perlman DC, Smith DJ, Reed JR, Hagan H. Use of the PRECIS-II instrument to categorize reports along the efficacy-effectiveness spectrum in an hepatitis C virus care continuum systematic review and meta-analysis. J Clin Epidemiol 2018;93:66-75. [PMID: 29102682 DOI: 10.1016/j.jclinepi.2017.10.015] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
61 Nosyk B, Min J, Pearce L, Zhou H, Homayra F, Wang L, Piske M, Mccarty D, Gardner G, O’briain W, Wood E, Daly P, Walsh T, Henry B. Development and validation of health system performance measures for opioid use disorder in British Columbia, Canada. Drug and Alcohol Dependence 2022;233:109375. [DOI: 10.1016/j.drugalcdep.2022.109375] [Reference Citation Analysis]
62 Kronfli N, Cox J. Care for people with hepatitis C in provincial and territorial prisons. CMAJ 2018;190:E93-4. [PMID: 29378868 DOI: 10.1503/cmaj.171142] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
63 Shin DJ, Trick AY, Hsieh YH, Thomas DL, Wang TH. Sample-to-Answer Droplet Magnetofluidic Platform for Point-of-Care Hepatitis C Viral Load Quantitation. Sci Rep 2018;8:9793. [PMID: 29955160 DOI: 10.1038/s41598-018-28124-3] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 5.5] [Reference Citation Analysis]
64 Trooskin SB, Poceta J, Towey CM, Yolken A, Rose JS, Luqman NL, Preston TW, Chan PA, Beckwith C, Feller SC, Lee H, Nunn AS. Results from a Geographically Focused, Community-Based HCV Screening, Linkage-to-Care and Patient Navigation Program. J Gen Intern Med 2015;30:950-7. [PMID: 25680353 DOI: 10.1007/s11606-015-3209-6] [Cited by in Crossref: 55] [Cited by in F6Publishing: 53] [Article Influence: 7.9] [Reference Citation Analysis]
65 Perlman DC, Jordan AE. Considerations for the Development of a Substance-Related Care and Prevention Continuum Model. Front Public Health 2017;5:180. [PMID: 28770195 DOI: 10.3389/fpubh.2017.00180] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
66 Linas BP, Morgan JR, Pho MT, Leff JA, Schackman BR, Horsburgh CR, Assoumou SA, Salomon JA, Weinstein MC, Freedberg KA, Kim AY. Cost Effectiveness and Cost Containment in the Era of Interferon-Free Therapies to Treat Hepatitis C Virus Genotype 1. Open Forum Infect Dis 2017;4:ofw266. [PMID: 28480259 DOI: 10.1093/ofid/ofw266] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
67 Greenaway C, Castelli F. Infectious diseases at different stages of migration: an expert review. J Travel Med 2019;26:taz007. [PMID: 30726941 DOI: 10.1093/jtm/taz007] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 14.5] [Reference Citation Analysis]
68 Teixeira PA, Bresnahan MP, Laraque F, Litwin AH, Shukla SJ, Schwartz JM, Reynoso S, Perumalswami PV, Weiss JM, Wyatt B, Schackman BR. Telementoring of primary care providers delivering hepatitis C treatment in New York City: Results from Project INSPIRE. Learn Health Syst 2018;2:e10056. [PMID: 31106275 DOI: 10.1002/lrh2.10056] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
69 Perlman DC, Des Jarlais DC, Feelemyer J. Can HIV and Hepatitis C Virus Infection be Eliminated Among Persons Who Inject Drugs? J Addict Dis 2015;34:198-205. [PMID: 26075647 DOI: 10.1080/10550887.2015.1059111] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
70 Tsui JI, Ko SC, Krupitsky E, Lioznov D, Chaisson CE, Gnatienko N, Samet JH. Insights on the Russian HCV Care Cascade: Minimal HCV Treatment for HIV/HCV Co-infected PWID in St. Petersburg. Hepatol Med Policy 2016;1:13. [PMID: 28217368 DOI: 10.1186/s41124-016-0020-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
71 Gutkind S, Starbird LE, Murphy SM, Teixeira PA, Gooden LK, Matheson T, Feaster DJ, Jain MK, Masson CL, Perlman DC, Del Rio C, Metsch LR, Schackman BR. Cost of Hepatitis C care facilitation for HIV/Hepatitis C Co-infected people who use drugs. Drug and Alcohol Dependence 2022;232:109265. [DOI: 10.1016/j.drugalcdep.2022.109265] [Reference Citation Analysis]
72 Perlman DC, Jordan AE, Uuskula A, Huong DT, Masson CL, Schackman BR, Des Jarlais DC. An international perspective on using opioid substitution treatment to improve hepatitis C prevention and care for people who inject drugs: Structural barriers and public health potential. Int J Drug Policy. 2015;26:1056-1063. [PMID: 26050614 DOI: 10.1016/j.drugpo.2015.04.015] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 4.0] [Reference Citation Analysis]
73 Palmer AY, Wade AJ, Draper B, Howell J, Doyle JS, Petrie D, Thompson AJ, Wilson DP, Hellard ME, Scott N. A cost-effectiveness analysis of primary versus hospital-based specialist care for direct acting antiviral hepatitis C treatment. Int J Drug Policy 2020;76:102633. [PMID: 31869656 DOI: 10.1016/j.drugpo.2019.102633] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
74 Jordan AE, Cleland CM, Wyka K, Schackman BR, Perlman DC, Nash D. Hepatitis C Virus Incidence in a Cohort in Medication-Assisted Treatment for Opioid Use Disorder in New York City. J Infect Dis 2020;222:S322-34. [PMID: 32877567 DOI: 10.1093/infdis/jiz659] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
75 Rhodes T, Egede S, Grenfell P, Paparini S, Duff C. The social life of HIV care: On the making of ‘care beyond the virus’. BioSocieties 2019;14:321-44. [DOI: 10.1057/s41292-018-0129-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
76 Kanwal F, Bacon BR, Beste LA, Brill JV, Gifford AL, Gordon SC, Horberg MA, Manthey JG, Reau N, Rustgi VK, Younossi ZM. Hepatitis C Virus Infection Care Pathway-A Report From the American Gastroenterological Association Institute HCV Care Pathway Work Group. Gastroenterology 2017;152:1588-98. [PMID: 28442121 DOI: 10.1053/j.gastro.2017.03.039] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
77 Kedziora DJ, Abeysuriya R, Kerr CC, Chadderdon GL, Harbuz VȘ, Metzger S, Wilson DP, Stuart RM. The Cascade Analysis Tool: software to analyze and optimize care cascades. Gates Open Res 2019;3:1488. [PMID: 31942536 DOI: 10.12688/gatesopenres.13031.2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
78 Ho SB, Bräu N, Cheung R, Liu L, Sanchez C, Sklar M, Phelps TE, Marcus SG, Wasil MM, Tisi A, Huynh L, Robinson SK, Gifford AL, Asch SM, Groessl EJ. Integrated Care Increases Treatment and Improves Outcomes of Patients With Chronic Hepatitis C Virus Infection and Psychiatric Illness or Substance Abuse. Clin Gastroenterol Hepatol 2015;13:2005-14.e1-3. [PMID: 25724704 DOI: 10.1016/j.cgh.2015.02.022] [Cited by in Crossref: 61] [Cited by in F6Publishing: 57] [Article Influence: 8.7] [Reference Citation Analysis]
79 Nguyen V, Higgs P. Rapid testing for hepatitis C does not infer current infection. Journal of Substance Use 2016;22:241-241. [DOI: 10.1080/14659891.2016.1208780] [Reference Citation Analysis]
80 Perlman DC, Jordan AE. Using qualitative data, people's perceptions, and the science of decision making to inform policy and improve hepatitis C care for people who use drugs. Int J Drug Policy 2015;26:217-9. [PMID: 25465345 DOI: 10.1016/j.drugpo.2014.10.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
81 Assoumou SA, Tasillo A, Leff JA, Schackman BR, Drainoni ML, Horsburgh CR, Barry MA, Regis C, Kim AY, Marshall A, Saxena S, Smith PC, Linas BP. Cost-Effectiveness of One-Time Hepatitis C Screening Strategies Among Adolescents and Young Adults in Primary Care Settings. Clin Infect Dis. 2018;66:376-384. [PMID: 29020317 DOI: 10.1093/cid/cix798] [Cited by in Crossref: 44] [Cited by in F6Publishing: 33] [Article Influence: 14.7] [Reference Citation Analysis]
82 Norton BL, Beitin A, Glenn M, DeLuca J, Litwin AH, Cunningham CO. Retention in buprenorphine treatment is associated with improved HCV care outcomes. J Subst Abuse Treat 2017;75:38-42. [PMID: 28237052 DOI: 10.1016/j.jsat.2017.01.015] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
83 Pho MT, Jensen DM, Meltzer DO, Kim AY, Linas BP. Clinical impact of treatment timing for chronic hepatitis C infection: a decision model. J Viral Hepat 2015;22:630-8. [PMID: 26135026 DOI: 10.1111/jvh.12412] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
84 Kronfli N, Linthwaite B, Kouyoumdjian F, Klein MB, Lebouché B, Sebastiani G, Cox J. Interventions to increase testing, linkage to care and treatment of hepatitis C virus (HCV) infection among people in prisons: A systematic review. Int J Drug Policy 2018;57:95-103. [PMID: 29715590 DOI: 10.1016/j.drugpo.2018.04.003] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 8.3] [Reference Citation Analysis]
85 Lambdin BH, Kral AH, Comfort M, Lopez AM, Lorvick J. Associations of criminal justice and substance use treatment involvement with HIV/HCV testing and the HIV treatment cascade among people who use drugs in Oakland, California. Addict Sci Clin Pract 2017;12:13. [PMID: 28610602 DOI: 10.1186/s13722-017-0078-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
86 Kronfli N, Dussault C, Klein MB, Lebouché B, Sebastiani G, Cox J. The hepatitis C virus cascade of care in a Quebec provincial prison: a retrospective cohort study. CMAJ Open 2019;7:E674-9. [PMID: 31796509 DOI: 10.9778/cmajo.20190068] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
87 Freiman JM, Tran TM, Schumacher SG, White LF, Ongarello S, Cohn J, Easterbrook PJ, Linas BP, Denkinger CM. Hepatitis C Core Antigen Testing for Diagnosis of Hepatitis C Virus Infection: A Systematic Review and Meta-analysis. Ann Intern Med 2016;165:345-55. [PMID: 27322622 DOI: 10.7326/M16-0065] [Cited by in Crossref: 94] [Cited by in F6Publishing: 42] [Article Influence: 15.7] [Reference Citation Analysis]
88 Rockstroh JK, Feld JJ, Chevaliez S, Cheng K, Wedemeyer H, Sarrazin C, Maasoumy B, Herman C, Hackett J Jr, Cohen DE, Dawson GJ, Cloherty G, Pawlotsky JM. HCV core antigen as an alternate test to HCV RNA for assessment of virologic responses to all-oral, interferon-free treatment in HCV genotype 1 infected patients. J Virol Methods 2017;245:14-8. [PMID: 28359920 DOI: 10.1016/j.jviromet.2017.03.002] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
89 Barocas JA, Savinkina A, Lodi S, Epstein RL, Bouton TC, Sperring H, Hsu HE, Jacobson KR, Schechter-Perkins EM, Linas BP, White LF. Projected long-term impact of the COVID-19 pandemic on hepatitis C outcomes in the United States: a modelling study. Clin Infect Dis 2021:ciab779. [PMID: 34499124 DOI: 10.1093/cid/ciab779] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
90 Tobin K, Clyde C, Davey-Rothwell M, Latkin C. Awareness and access to naloxone necessary but not sufficient: Examining gaps in the naloxone cascade. Int J Drug Policy 2018;59:94-7. [PMID: 30075401 DOI: 10.1016/j.drugpo.2018.07.003] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 6.5] [Reference Citation Analysis]